Skip to content

Study · Observational study · n = 341 · 2025

4 results

Diagnostic accuracy of the triptorelin stimulation test for central precocious puberty in girls.

Chioma L, Bizzarri C, Longobardi M, Mainieri F, Porzio O, D'Agostini M, Paone L, Bottaro G, Cianfarani S

Endocrine connections12 Dec 2025Cited by 1 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyActivity measurement

    In girls referred for suspected precocious puberty, intravenous gonadorelin produced significantly lower FSH peaks than triptorelin.

    In plain wordsIn girls with suspected early puberty, gonadorelin produced lower FSH peaks than triptorelin.

    Outcome
    DecreaseFSH peak after stimulation
    Study

    n = 341

    Comparator
    Subcutaneous triptorelin
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    Triptorelin elicited significantly higher FSH peaks than gonadorelin
    2 context sentences
    Summary · context
    This retrospective study evaluated the diagnostic accuracy of subcutaneous triptorelin compared with intravenous gonadorelin and investigated the optimal timing for LH peak assessment.
    Summary · context
    A total of 341 girls referred for suspected precocious puberty were evaluated: 102 underwent the triptorelin test and 239 the gonadorelin test, with gonadotropins measured by electrochemiluminescence assay at baseline and after stimulation.
  2. 02HumanObservational studyActivity measurement

    In girls referred for suspected precocious puberty, LH peaks after gonadorelin were comparable to those after triptorelin.

    In plain wordsIn girls with suspected early puberty, gonadorelin and triptorelin gave comparable LH peaks.

    Outcome
    No significant changeLH peak after stimulation
    Study

    n = 341

    Comparator
    Subcutaneous triptorelin
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    Triptorelin elicited significantly higher FSH peaks than gonadorelin, while LH peaks were comparable; consequently, FSH/LH ratios were higher after triptorelin.
    2 context sentences
    Summary · context
    This retrospective study evaluated the diagnostic accuracy of subcutaneous triptorelin compared with intravenous gonadorelin and investigated the optimal timing for LH peak assessment.
    Summary · context
    A total of 341 girls referred for suspected precocious puberty were evaluated: 102 underwent the triptorelin test and 239 the gonadorelin test, with gonadotropins measured by electrochemiluminescence assay at baseline and after stimulation.
  3. 03HumanObservational studyActivity measurement

    In girls referred for suspected precocious puberty, FSH/LH ratios were lower after gonadorelin than after triptorelin.

    In plain wordsIn girls with suspected early puberty, FSH/LH ratios were lower after gonadorelin than after triptorelin.

    Outcome
    DecreaseFSH/LH ratio after stimulation
    Study

    n = 341

    Comparator
    Subcutaneous triptorelin
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    Triptorelin elicited significantly higher FSH peaks than gonadorelin, while LH peaks were comparable; consequently, FSH/LH ratios were higher after triptorelin.
    2 context sentences
    Summary · context
    This retrospective study evaluated the diagnostic accuracy of subcutaneous triptorelin compared with intravenous gonadorelin and investigated the optimal timing for LH peak assessment.
    Summary · context
    A total of 341 girls referred for suspected precocious puberty were evaluated: 102 underwent the triptorelin test and 239 the gonadorelin test, with gonadotropins measured by electrochemiluminescence assay at baseline and after stimulation.
  4. 04HumanObservational studyOther

    In girls tested with intravenous gonadorelin, an LH peak cut-off of 4.7 IU/L separated central precocious puberty from non-progressive thelarche with sensitivity 100%, specificity 87% and AUC 0.982.

    In plain wordsIn girls tested with gonadorelin, an LH peak cut-off of 4.7 IU/L identified central precocious puberty with 100% sensitivity and 87% specificity.

    Outcome
    Not applicableDiagnostic accuracy of LH peak cut-off after gonadorelin
    Study

    n = 239

    Comparator
    Subcutaneous triptorelin
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Measurements

    LH peak cut-off
    4.7 IU/L
    gonadorelin
    Sensitivity
    100%
    gonadorelin
    Specificity
    87%
    gonadorelin
    AUC
    0.982
    gonadorelin

    Source sentences

    Summary
    while a threshold of 4.7 IU/L was observed after gonadorelin (sensitivity 100%, specificity 87%; AUC 0.982).
    3 context sentences
    Summary · context
    Based on clinical, radiological, and laboratory criteria, 143 girls were diagnosed with CPP and 198 with non-progressive thelarche (NPT).
    Summary · context
    This retrospective study evaluated the diagnostic accuracy of subcutaneous triptorelin compared with intravenous gonadorelin and investigated the optimal timing for LH peak assessment.
    Summary · context
    A total of 341 girls referred for suspected precocious puberty were evaluated: 102 underwent the triptorelin test and 239 the gonadorelin test, with gonadotropins measured by electrochemiluminescence assay at baseline and after stimulation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    13 Oct 2026, 21:44 UTC

    Study results updated

  3. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.